CRISPR Therapeutics (CRSP, Financials) stock rose 16.4% to $50.60 as of 10:10 a.m. GMT-5 on Friday, following an analyst upgrade.
Citing pipeline advancements and possible catalysts, Evercore ISI analyst Liisa Bayko raised CRISpen Therapeutics from "In Line" to "Outperform." The company focused on the CTX320 and CTX310 in vivo gene editing initiatives, giving respectively 10% and 5% success rates. Second quarter of 2025 data from CTX320 is anticipated to line up with Novartis's cardiovascular outcomes study. Mid-2025 should provide updates on CTX112 (CAR-T treatment), CTX131 (oncology), and CTX221 (type 1 diabetes).
From $1.7 billion at the end of 2023, the corporation said in December 31, 2024, $1.9 billion in cash, cash equivalents, and marketable securities. Compared with 40 at the end of October, the Casgevy cell collection program also grew with over 50 fresh collections in the last nine weeks of the fourth quarter.
Although the firm's risk-adjusted model puts in low success probability for its new in vivo activities, its financial situation and clinical advancements indicate a better picture.
